Barclays Raises Kodiak Sciences (NASDAQ:KOD) Price Target to $4.00

Kodiak Sciences (NASDAQ:KOD) had its price objective boosted by Barclays from $3.00 to $4.00 in a research note released on Friday morning,Benzinga reports. The firm currently has an underweight rating on the stock.

Separately, HC Wainwright reiterated a “neutral” rating and set a $3.00 price target on shares of Kodiak Sciences in a report on Friday.

Kodiak Sciences Stock Performance

KOD stock opened at $5.66 on Friday. The stock’s 50 day moving average price is $3.42 and its 200 day moving average price is $3.06. The firm has a market cap of $297.83 million, a P/E ratio of -1.55 and a beta of 2.26. Kodiak Sciences has a 1 year low of $2.18 and a 1 year high of $7.77.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in KOD. SG Americas Securities LLC acquired a new stake in shares of Kodiak Sciences during the third quarter valued at about $33,000. Meeder Asset Management Inc. bought a new stake in Kodiak Sciences in the second quarter valued at about $36,000. Sanctuary Advisors LLC acquired a new stake in Kodiak Sciences during the second quarter valued at approximately $36,000. LJI Wealth Management LLC raised its position in shares of Kodiak Sciences by 21.3% during the 3rd quarter. LJI Wealth Management LLC now owns 17,100 shares of the company’s stock valued at $45,000 after acquiring an additional 3,000 shares in the last quarter. Finally, Headlands Technologies LLC acquired a new stake in shares of Kodiak Sciences during the first quarter worth $50,000. 89.06% of the stock is owned by institutional investors and hedge funds.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.